Clinical Topics & News
News
Has the time come for glucose monitors for people without diabetes?
The increasing popularity of continuous glucose monitoring devices in prediabetes and for ‘wellness’ prompts discussion about appropriate use and...
Conference Coverage
New dual-agonist weight-loss injection impressive, but early days
The “bottom line” is that this potential new antiobesity/diabetes drug is “very promising, but [it is] still a little early to say where it...
Conference Coverage
Tirzepatide lowers weight across all groups with obesity
The antiobesity medication semaglutide “took things up one big notch, and now tirzepatide is up a little notch above that,” one expert said.
Conference Coverage
If a saphenous graft is available, treat limb threatening ischemia surgically
Surgery beats endovascular treatment for limb threatening ischemia when saphenous grafts are an option, according to the BEST-CLI trial.
News
Finerenone: ‘Striking’ cut in pneumonia, COVID-19 risks
Secondary analyses of the finerenone pivotal trials showed that the agent was linked with less infective pneumonia and blunted COVID-19 severity...
News
Yoga and other mind-body work good for diabetes control
Mind-body practices can control fasting blood glucose and A1c to a clinically significant extent, thus offering an effective complementary...
News
Insulin rationing common, ‘surprising’ even among privately insured
Americans with private insurance are more likely to ration insulin than are those with public health insurance and the insulin-treated diabetes...
News
Diabetes becoming less potent risk factor for CVD events
Diabetes is no longer equal to cardiovascular disease as a risk factor for cardiovascular events, according to a population-based study in Ontario...
News
Finerenone benefits T2D across spectrum of renal function
Finerenone treatment of people with type 2 diabetes and albuminuria improved outcomes, compared with placebo regardless of renal functional status...
Conference Coverage
Tirzepatide’s benefits expand: Lean mass up, serum lipids down
New results from the SURMOUNT-1 trial of tirzepatide in people with obesity show further positive effects.